Trial Profile
A phase IIa, open-label, multi-center, parallel group, pharmacokinetic interaction study of faldaprevir and deleobuvir (BI 207127) and their effect on CYP-mediated metabolism in patients with chronic genotype 1 HCV infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary) ; Deleobuvir
- Indications Hepatitis C
- Focus Pharmacokinetics
- 14 Dec 2015 New trial record
- 05 Nov 2013 Results of an interim analysis presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases